RBC Capital on Edgewise Therapeutics (EWTX): ' We Would Be Buyers on Weakness'
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $48.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
